A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors (ATLAS-INH)
ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX
Sponsor: Genzyme, a Sanofi Company
This PHASE3 trial investigates Hemophilia A and Hemophilia B and is currently completed. Genzyme, a Sanofi Company leads this study, which shows 20 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
20 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2022 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 15 earlier versions
-
Sep 2021 — Jan 2022 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
May 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Apr 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE3
-
Jun 2019 — Feb 2020 [monthly]
Recruiting PHASE3
-
Feb 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Sep 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Genzyme, a Sanofi Company
For direct contact, visit the study record on ClinicalTrials.gov .